Biotechnology company OncoSec Medical Incorporated (NASDAQ:ONCS) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) Investigational New Drug (IND) application for the first-in-human Phase 1 trial for its CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2, in partnership with Providence Cancer Institute, a part of Providence St Joseph Health.
The CORVax combines OncoSec's immuno-stimulant IL-12 expression platform, TAVO (tavokinogene telseplasmid), with a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed at the National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) and which has been licensed to OncoSec on a non-exclusive basis.
Under the terms of the agreement, Providence will begin a Phase 1, open-label study to evaluate the safety and immunogenicity of a plasmid encoding the SARS-CoV-2 spike protein alone or in combination with IL-12 (CORVax12, SARS-CoV-2 S glycoprotein plasmid DNA in combination with IL-12 plasmid) in up to 36 healthy volunteers.
In conjunction with the agreement, CORVax12 will be given as a prime and booster dose four weeks apart. The subjects will be subdivided in parallel age cohorts of 18-55 years old versus > 55 years old, added the company.
According to the companies, CORVax12 is the only DNA vaccine that uses an immune stimulant to promote an immune response against the SARS-CoV-2 virus. The CORVax vaccine approach combines the co-administration of TAVO (plasmid IL-12) with a DNA-encodable version of the SARS-CoV-2 spike or S glycoprotein to enhance immunogenicity of the component developed at NIAID Vaccine Research Center.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study